An analytical comparison between point-of-care uric acid testing meters

被引：15

作者：

Paraskos, Jonathan ^{[1
]}

Berke, Zsofia ^{[2
]}

Cook, Jason ^{[2
]}

Miner, Jeffrey N. ^{[3
]}

Braddock, Martin ^{[1
]}

Platt, Adam ^{[4
]}

Hughes, Glen ^{[1
]}

机构：

[1] AstraZeneca, Res & Dev, Macclesfield, Cheshire, England

[2] AstraZeneca, Res & Dev, Molndal, Sweden

[3] Ardea Biosci, Res & Dev, San Diego, CA USA

[4] AstraZeneca, Compan Diagnost, Cambridge, England

来源：

EXPERT REVIEW OF MOLECULAR DIAGNOSTICS | 2016年 / 16卷 / 03期

关键词：

gout; diagnostic test; point-of-care systems; Uric acid; GOUT; HYPERURICEMIA; ALLOPURINOL; FEBUXOSTAT; MANAGEMENT; URATE; TRIAL;

D O I：

10.1586/14737159.2016.1134326

中图分类号：

R36 [病理学];

学科分类号：

100104 ;

摘要：

Objective: A key goal in gout treatment is achieving sustained serum uric acid (sUA) lowering. Point-of-care test (PoCT) meters provide convenient, rapid measures of sUA levels to monitor/adjust therapy. Four commercially available sUA PoCT meters were compared qualitatively (ease of use) and quantitatively (precision/accuracy). Methods: Liquid chromatography mass spectrometry (LC-MS) analysis was used as a laboratory reference method to compare precision of PoCT devices using blood samples from 20 healthy volunteers. Accuracy was compared against the LC-MS reference method and a laboratory clinical chemistry platform. Results: Qualitatively, EasyTouch((R)) GU and UASure were least user-friendly, requiring repeated attempts for accurate use. HumaSens and BeneCheck provided good usability and assay precision. Cross-validation of meter precision with laboratory-based uricase assay gave good correlations between both methods (R-2=0.8061 and 0.7605, respectively). Conclusion: UA PoCT meters can be important in managing gout, and the characteristics compared herein may enhance successful patient uptake.

引用

页码：373 / 382

页数：10

共 25 条

[21]

Terkeltaub R, 2013, GOUT DIAGNOIS MANAGE

[22] Update on gout: new therapeutic strategies and options [J].

Terkeltaub, Robert .

NATURE REVIEWS RHEUMATOLOGY, 2010, 6 (01) :30-38

[23] Disease-related and all-cause health care costs of elderly patients with gout [J].

Wu, Eric Q. ;

Patel, Pankaj A. ;

Yu, Andrew P. ;

Mody, Reema R. ;

Cahill, Kevin E. ;

Tang, Jackson ;

Krishnan, Eswar .

JOURNAL OF MANAGED CARE PHARMACY, 2008, 14 (02) :164-175

[24] EULAR evidence based recommendations for gout.: Part II:: Management.: Report of a task force of the EULAR standing committee for international clinical studies including therapeutics (ESCISIT) [J].

Zhang, W. ;

Doherty, M. ;

Bardin, T. ;

Pascual, E. ;

Barskova, V. ;

Conaghan, P. ;

Gerster, J. ;

Jacobs, J. ;

Leeb, B. ;

Liote, F. ;

McCarthy, G. ;

Netter, P. ;

Nuki, G. ;

Perez-Ruiz, F. ;

Pignone, A. ;

Pimentao, J. ;

Punzi, L. ;

Roddy, E. ;

Uhlig, T. ;

Zimmermann-Gorska, I. .

ANNALS OF THE RHEUMATIC DISEASES, 2006, 65 (10) :1312-1324

[25] Uricase based methods for determination of uric acid in serum [J].

Zhao, Yunsheng ;

Yang, Xiaoyan ;

Lu, Wei ;

Liao, Hong ;

Liao, Fei .

MICROCHIMICA ACTA, 2009, 164 (1-2) :1-6

← 1 2 3 →